Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOKE plus: Oral semaglutide in early Alzheimer's disease
jRCT2031210117Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing Oral semaglutide once daily with Placebo once daily (2 arms). Primary endpoint: Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB). Started Jul 2021; status: active, not recruiting.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031210117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210117.